LBRX
What one share of Lb Pharmaceuticals holds
Pharmaceutical Preparations
We are a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder and other diseases.
Lb Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.81 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.69 |
| Cash and investments | $11.43 |
| Book value | $11.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$176.15 | $2.15 | −$150.24 | — | −$375.73 |
| 2025 | — | −$3.13 | $0.01 | −$4.38 | — | $11.91 |